Business
Resverlogix Announces New Research Highlighting Apabetalone's Potential Benefits in Cardiovascular Disease, Heart Failure, and COVID-19
Calgary, Alberta--(Newsfile Corp. - March 2, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix")...
About this update from Resverlogix Corp.
[{"type":"text","content":"Resverlogix Announces New Research Highlighting Apabetalone's Potential Benefits in Cardiovascular Disease, Heart Failure, and COVID-19Calgary, Alberta--(Newsfile Corp. - March 2, 2023) - Resverlogix Corp. (TSX: RVX) (\"Resverlogix\") today announced the publication of two articles in peer-reviewed scientific journals. The first, entitled \"Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation\" by Fu et al., was published in International Immunopharmacology, and positions apabetalone as a variant-independent therapeutic for post COVID-19 conditions.The article is published online HERE.International Immunopharmacology Publication Highlights Include:SARS-CoV-2, the virus responsible for COVID-19, binds human lung cells via interaction of the viral spike protein and the cell surface receptor called angiotensin converting enzyme 2 (ACE2)Apabetalone treatment reduces ACE2 to decrease binding of viral spike proteins including spike proteins from both the Delta and Omicron variantsApabetalone treatment also opposes the induction of COVID-related inflammatory mediators, in response to virus-mimicking stimulation of human lung cellsThis research highlights apabetalone's potential to counter short- and long-term pathologic consequences of the SARS-CoV-2 virus, and positions it as a \"variant-independent COVID therapeutic\"The second article, \"Epigenetic BET reader inhibitor apabetalone (RVX-208) counters proinflammatory aortic gene expression in a diet induced obesity mouse model and in human endothelial cells\" by Wasiak et al., was published in Atherosclerosis, and provides new mechanistic insights in to apabetalone's reduction of cardiovascular risk in obese patients. The article is published online HERE.Atherosclerosis Publication Highlights Include:Apabetalone treatment was evaluated in a diet induced obesity (DIO) mouse modelMice on a high-fat diet had greater levels of vascular inflammation markers in the aorta, compared with those on a low-fat dietApabetalone treatment reduced the expression of pro-inflammatory genes in the high-fat diet fed mice compared to untreated controlsVascular inflammation is prevalent in obese patients and is a significant driver of negative cardiac eventsThis study helps us better understand the mec...